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Cancers with viral aetiologies can potentially be prevented by antiviral vaccines. Therefore, it is
important to understand how viral infections and cancers might be linked. Some cancers
frequently carry gammaherpesvirus genomes. However, they generally express the same viral
genes as non-transformed cells, and differ mainly in also carrying oncogenic host mutations.
Infection, therefore, seems to play a triggering or accessory role in disease. The hit-and-run
hypothesis proposes that cumulative host mutations can allow viral genomes to be lost entirely,
such that cancers remaining virus-positive represent only a fraction of those to which infection
contributes. This would have considerable implications for disease control. However, the hit-and-
run hypothesis has so far lacked experimental support. Here, we tested it by using Cre–lox
recombination to trigger transforming mutations in virus-infected cells. Thus, ‘floxed’ oncogene
mice were infected with Cre recombinase-positive murid herpesvirus-4 (MuHV-4). The emerging
cancers showed the expected genetic changes but, by the time of presentation, almost all lacked
viral genomes. Vaccination with a non-persistent MuHV-4 mutant nonetheless conferred
complete protection. Equivalent human gammaherpesvirus vaccines could therefore potentially
prevent not only viral genome-positive cancers, but possibly also some cancers less suspected of
a viral origin because of viral genome loss.
INTRODUCTION
The identification of viral aetiologies for hepatic
(Blumberg, 1997) and cervical (Frazer, 2004) cancers has
made antiviral vaccination a relatively simple and effective
means of disease prevention. Human gammaherpesviruses –
Epstein–Barr virus (EBV) and Kaposi’s sarcoma-asso-
ciated herpesvirus (KSHV) – are also oncogenic, but
the lack of single, unifying features of the associated
cancers has made it unclear how directly infection and
disease are linked and so what vaccination might achieve.
The robust persistence of herpesviruses in immunocom-
petent hosts also makes vaccination a considerable
challenge.
EBV transforms B cells in vitro and, in immunocomprom-
ised patients, the viral genes responsible for transformation
can cause disease (Carbone et al., 2009). However, EBV-
infected cancers in immunocompetent hosts tend to
express the same viral genes as non-transformed cells.
They differ in also carrying oncogenic host mutations;
indeed, Burkitt’s lymphoma is associated more strongly
with c-myc translocation than with EBV infection
(Thorley-Lawson & Allday, 2008). Thus, viral genes seem
mostly to have triggering or accessory roles in disease, with
host oncogenes being the main drivers. The hit-and-run
hypothesis proposes that viral genomes initiating disease
can be lost entirely to obscure a cancer’s viral origin
(Ambinder, 2000). Early on, viral genes are likely to be
essential for cancer-cell survival (Hammerschmidt &
Sugden, 2004). However, cancers accumulate vast numbers
of host mutations (Pleasance et al., 2010), some of which
will inevitably promote more autonomous growth. Thus, it
seems inevitable that a cancer will, with time, evolve
increasing independence from viral gene functions that
could allow viral genome loss.
The main problem with the hit-and-run hypothesis has been
a lack of experimental support. Analyses of gammaherpes-
virus-induced cancers have focused on African Burkitt’s
lymphoma,nasopharyngealcarcinomaandKaposi’ssarcoma,
because their high frequencies of viral genome retention make
plausible a causal link between infection and disease.
However, focusing on virus-positive cancers tells us little
about genome loss, as here most presenting cancers would be
virus-negative. Instead, it is necessary to track prospectively
the fate of viral genomes in transformed cells. In vitro,B - c e l l
cancers tend to maintain gammaherpesvirus genomes,
whereas Kaposi’s sarcoma and nasopharyngeal carcinoma
tendtolosethem (Ganem,2006;Dittmeret al., 2008). In vivo,
murid herpesvirus-4 (MuHV-4) infection increases the
incidence of virus-negative cancers (Sunil-Chandra et al.,
1994; Tarakanova et al., 2005). However, the difficulty of
analysing spontaneous cancers, where the molecular changes
driving transformation are almost always unknown, makes
firm functional conclusions hard to draw. To ensure that the
host factors contributing to cancer remained known, we used
Cre–lox recombination in a well-established conditional
mouse cancer model (reviewed by DuPage et al., 2009) to
transform virus-infected cells, andthen analysed the emerging
cancers for viral genome retention.
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Generation of Cre
+ MuHV-4
We inserted a human cytomegalovirus (HCMV) IE1
promoter-driven Cre expression cassette between the 39
ends of MuHV-4 ORFs 57 and 58 (Fig. 1a, b). We used an
HCMV IE1 promoter because this can be active in latently
infected cells (Rosa et al., 2007; Smith et al., 2007). Thus,
Cre could be expressed without MuHV-4 lytic genes kill-
ing the infected cells. Two functionally indistiguishable
mutants were obtained. Both showed Cre expression by
excising spontaneously their loxP-flanked bacterial artificial
chromosome (BAC) cassettes, and immunofluorescence
showed Cre expression in infected-cell nuclei (Fig. 1c).
(The Cre coding sequence used incorporates an N-terminal
nuclear-localization signal.)
In vivo loxP recombination by Cre
+ MuHV-4
We tested whether viral Cre expression could recombine
loxP sites in the host genome by infecting mouse
embryonic fibroblasts derived from ROSA26-lacZ
flox/flox
reporter mice (Fig. 2a). b-Galactosidase assays were
strongly positive, indicating loxP recombination. Such
recombination was also achieved by infecting ROSA26-
lacZ
flox/flox mice intraperitoneally (i.p.) with Cre
+ MuHV-
4 (Fig. 2b): widespread b-galactosidase expression was
evident on the diaphragm, a site commonly infected by i.p.
MuHV-4 (Milho et al., 2009).
We then infected p53
flox/floxK-ras
LSL-G12D/+ mice i.p. with
Cre
+ MuHV-4 (Fig. 2c, d). More than 90% of infected
mice developed cancers within 3 months, compared with
0% of uninfected or wild-type MuHV-infected controls.
Cancers occurred most frequently on the diaphragm.
Disease was rare within 30 days, and most cancers were
single lesions. In contrast, virus replication was widespread:
3 days after inoculation, spleens yielded (2.1±1.2)610
4
and peritoneal washes (1.7±1.2)610
3 infectious centres
per mouse (mean±SD titres, n56, with lytic titres ,1%of
infectious centre titres); even 2 months later, spleens
yielded (2.2±1.5)610
2 infectious centres per mouse
(n56). Therefore, cancer growth was much more restricted
than viral latency and functional Cre expression.
Analysis of virus-triggered cancers
All of the cancers analysed (n.12) were histological
sarcomas (Fig. 3a). In situ hybridization (Fig. 3b) showed
surprisingly littleexpression oftheMuHV-4tRNAsnormally
abundant in lytic and latent infections (Bowden et al.,1 9 9 7 ) .
At most, a few positive cells were scattered around the main
cancer mass. Real-time PCR (Fig. 3c) established that
sarcomas contained lower copy numbers of viral genomes
than latently infected spleens of the same mice.
Fig. 1. Characterization of Cre
+ MuHV-4. (a) An HCMV IE1 promoter-driven Cre expression cassette was inserted between
MuHV-4 ORFs 57 and 58. Relevant restriction sites are shown. (b) Viral DNA was digested with HindIII or BglII and probed
with either a genomic BglII clone or the HCMV IE1–Cre construct, as shown in (a). WT, Wild-type; Cre
+, recombinant;
Cre
+ind, independently derived recombinant. (c) BHK-21 cells were infected with wild-type or Cre
+ MuHV-4 (1 p.f.u. per cell,
16 h), then fixed, permeabilized and stained for Cre recombinase or for MuHV-4 antigens using polyclonal rabbit sera. Nuclei
were counterstained with DAPI.
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phages and fibroblasts (Fig. 4a, b), but only fibroblasts
grew out. Thirteen of 20 explants yielded infectious virus.
Viral spread soon overwhelmed these positive cultures,
consistent with fibroblasts being highly permissive for
MuHV-4 lytic replication. The others remained virus-
negative. At 2 days post-explant, titres were low in all
cultures (,1 p.f.u. per 10
4 cells), and ,5% of fibroblasts
cloned at this time (39 of 744 clones from eight mice)
yielded infectious virus. Clones lacking infectious virus also
lacked viral genomes by PCR (Fig. 4c) and Southern
blotting (Fig. 4d). Nevertheless, all sarcomas showed the
expected patterns of Cre-induced p53 disruption and k-
ras(G12D) expression (Fig. 5). Therefore, the vast majority
of cancer cells showed genetic changes consistent with
previous virus infection but, by the time of presentation,
were not virus-infected.
A trivial explanation for the lack of viral genomes in
transformed cells would be that Cre uptake from infected-
cell debris was sufficient for transformation. However,
infecting p53
flox/floxK-ras
LSL-G12D/+ mice (n524) with
herpes simplex virus (HSV) expressing Cre from an
HCMV IE1 promoter caused no disease. Also, Cre
+ HSV
similarly shows no spread of Cre signal in vivo (Proenc ¸a
et al., 2008), and Cre
+ MuHV-4 plaque assays on
ROSA26-lacZ
flox/flox fibroblasts showed no obvious spread
of b-galactosidase expression to uninfected cells.
Even when virus was recovered from cancer cells, it might
have come from infiltrating, non-transformed cells rather
than being that responsible for the original oncogenic hit.
We examined this possibility by infecting mice with a mix
of Cre
+ and Cre
2 MuHV-4 and typing the virus recovered
from sarcomas for Cre expression. Cre
+ MuHV-4 showed
approximately 30-fold lower latent titres than Cre
2 virus,
so we used an input Cre
+/Cre
2 mixture of 30:1. Only one
of 18 virus-positive sarcoma explants was Cre
+ by
immunofluorescence. PCR and DNA sequencing of the
ORF57/58 junction showed that the Cre
2 viruses were
wild-type. This did not cause sarcomas (Fig. 2), so even
when virus infection was observed in sarcoma explants, it
appeared rarely to be that responsible for transformation.
Vaccination against virus-triggered cancers
The high efficiency of virus-triggered oncogenesis in our
model suggested that vaccine-induced protection might be
difficult to achieve. However, when Cre was substituted for
ORF50 to make a replication-deficient Cre
+ MuHV-4,
both i.p. and intranasal (i.n.) infections gave no disease in
p53
flox/floxK-ras
LSL-G12D/+ mice over 5 months (n530).
Fig. 2. Cre recombinase-triggered cancers in MuHV-4-infected
mice. (a) Embryonic fibroblasts from ROSA26-lacZ
flox/flox mice
were infected (0.3 p.f.u. per cell, 16 h) with either wild-type or
Cre
+ MuHV-4, then fixed and incubated with X-Gal to reveal b-
galactosidase expression, indicating Cre-mediated recombination.
Arrowheads show examples of positive staining. (b) ROSA26-
lacZ
flox/flox mice were infected i.p. with Cre
+ MuHV-4. Three days
later, diaphragms were stained post-mortem for b-galactosidase
expression with X-Gal. Representative images from two mice are
shown. (c) p53
flox/floxK-ras
LSL-G12D/+ mice were infected i.p. with
wild-type or Cre
+ MuHV-4. All of the former mice remained
healthy; all but one of those infected with Cre
+ MuHV-4
developed cancers within 3 months. Equivalent results were
obtained in three further experiments. (d) A typical i.p. cancer.
P. G. Stevenson and others
2178 Journal of General Virology 91This lack of disease without lytic spread suggested that
vaccination might still work – for example, the cells first
encountered by incoming virions might not be trans-
formed by k-ras. We therefore immunized p53
flox/flox
K-ras
LSL-G12D/+ mice either i.n. or i.p. with ORF73
2Cre
2
MuHV-4, which lacks episome maintenance and so fails to
persist in vivo (Fowler et al., 2003; Moorman et al., 2003).
This protected completely against Cre
+ virus challenge
(Fig. 6).
As a further test of vaccine efficacy, we established an i.n.
Cre
+ virus challenge model (Fig. 7). This caused a more
rapid illness than i.p. infection, with weight loss and
respiratory difficulties as early as 7 days post-inocu-
lation. The lungs of infected mice became grossly
enlarged, and histological examination (Fig. 7a) showed
extensive cell proliferation obliterating the alveolar air
spaces. p53
flox/floxK-ras
LSL-G12D/+ mice infected with
Cre
2 MuHV-4 and p53
flox/flox mice infected with Cre
+
MuHV-4 remained clinically well, so disease again
reflected k-ras activation. In situ hybridization (Fig. 7b)
showed viral tRNA expression in acutely infected lungs
and lymphoid tissue, but not in diseased lungs.
Therefore, viral genomes were again lost rapidly from
the transformed cells. Vaccination i.p. with Cre
2ORF73
2
MuHV-4 protected completely against both macroscopic
and microscopic disease (Fig. 7c–e). It also protected
against the milder histological changes induced by Cre
+
MuHV-4 in p53
flox/flox mice (Fig. 8).
DISCUSSION
A viral aetiology is rarely considered for cancers that lack
viral genomes. Our data show that cells driven to
proliferate by host oncogenes readily lose gammaherpes-
virus genomes in vivo. Relying on viral genome detection to
establish aetiology could therefore underestimate the
number of cancers to which gammaherpesviruses contrib-
ute. Most analyses of human cancers have focused on
examples of genome retention. The hypothesis that these
viral genomes contribute to disease (Hammerschmidt &
Sugden, 2004) makes sense, as there must be a growth
advantage to offset any immune recognition of viral
antigens. Thus, whilst EBV genes seem not to drive the
growth of EBV
+ Burkitt’s lymphoma directly (Kang et al.,
2005), they may still provide important co-factors
(Thorley-Lawson & Allday, 2008). However, the retention
of viral genomes by some cancer types does not establish
that viral genome retention is the norm. Interestingly,
whilst EBV
+ Burkitt’s lymphoma is associated strongly
with immunosuppressive malaria infection, EBV
2 Burkitt’s
Fig. 3. MuHV-4-triggered sarcomas. (a) Representative haematoxylin/eosin-stained sections from p53
flox/floxK-ras
LSL-G12D/+
mice infected with Cre
+ MuHV-4. Bar, 100 mm. (b) Cancer or spleen sections of Cre
+ MuHV-4-infected p53
flox/flox
K-ras
LSL-G12D/+ mice were probed for MuHV-4 tRNAs 1–4. Representative images are shown. Arrowheads show positive
cells. Bar, 100 mm. (c) DNA samples from paired cancers and spleens were analysed for viral genome copy number by
quantitative PCR. Each viral copy number is expressed relative to the cellular DNA copy number in the same sample.
Viral genome loss
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Thus, in immunocompetent hosts, EBV genome loss may
be required for cancers to evolve.
Viral antigen recognition (Rickinson & Moss, 1997)
provides a context for understanding both genome-positive
and genome-negative cancers. Cells driven to proliferate by
the EBV growth programme are normally killed by
antiviral T cells, so EBV-driven cancers are limited to the
immunocompromised. In contrast, host mutations drive
non-immunogenic cell proliferation even when the viral
growth programme is turned off. This creates a new
balance: viral genes are now required only for accessory
roles, allowing viral antigen recognition to be reduced.
However, some immune control may still occur – for
example, the evasion of antigen presentation by gamma-
herpesvirus episome-maintenance proteins (Yin et al.,
2003; Bennett et al., 2005) can fail at high proliferation
rates (Mu ¨nz, 2004). Also, the accumulation of host
mutations is unlikely to stop. If host mutations alone
remain insufficient to maintain transformation, cancer
cells losing viral genomes will themselves be lost; however,
if host mutations become sufficient, then antiviral T cells
can select for viral genome loss.
The predominance of sarcomas in our model was
surprising, as MuHV-4 classically persists in B cells
(Sunil-Chandra et al., 1992). However, stromal cells may
also be an important site of persistence (Stewart et al.,
1998; Sua ´rez and van Dyk, 2008) – consistent with such an
idea, ORF50
2 MuHV-4 genomes were well-maintained
over 3 weeks in both BHK-21 and p53
2/2K-ras
LSL-G12D/+
fibroblasts (data not shown). Stromal cells may also be
more sensitive than B cells to transformation by k-ras
(Nicolaides et al., 1994; Janssen et al., 2005). A key point is
that known viral tropisms do not necessarily predict the
cell type of virus-triggered cancers. Thus, hit-and-run
oncogenesis may be more relevant to rarely EBV
+ cancers
Fig. 4. Analysis of explanted cancer cells from Cre
+ MuHV-4-infected p53
flox/floxK-ras
LSL-G12D/+ mice. (a) A typical
phase-contrast image of a primary cancer culture 1 day post-explant. (b) Immunostaining of a primary cancer culture at
3 days post-explant shows typical VCAM-1
+CD44
+CD138
+ fibroblasts, and some F4/80
+ macrophages. Occasional
fibroblasts (,1%) were viral antigen-positive, shown here by staining for the ORF75c tegument protein. (c) Cloned
cancer cells were analysed for viral genomes by quantitative PCR. Viral DNA copy numbers are expressed relative to
cellular DNA copy numbers. Only clone 10 yielded infectious virus; below the dashed line (,1 viral genome per 100 cell
genomes), clones were considered virus-negative. (d) A subset of the clones in (c) was further analysed by probing PstI-
digested DNA (1 mg per lane5500000 cells) for the MuHV-4 1.2 kb terminal repeat (approx. 30 copies per genome) by
Southern blotting. One picogram of plasmid DNA5200000 copies, so no detectable viral genomes implies ,1c o p yp e r
75 cells.
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Young, 2009) than to those of B cells. Even in
transformed fibroblasts, MuHV-4 (unlike HSV) is far
from uniformly lytic (May et al., 2004), and productive
MuHV-4 spread is strongly constrained in vivo by host
immunity. Therefore, it would seem quite feasible for a
virus-positive cancer to develop in a cell type permissive
for lytic replication.
There is no certain way to identify a human cancer as
previously virus-positive once it becomes virus-negative, so
human gammaherpesvirus disease burdens may only be
revealed by vaccination. This is not necessarily straight-
forward: subunit vaccines have so far failed to limit
gammaherpesvirus persistence (Sokal et al.,2 0 0 7 ;
Stevenson et al., 2009). However, live-attenuated vaccines
can reduce MuHV-4 latent loads (Tibbetts et al., 2003;
Boname et al., 2004; Fowler & Efstathiou, 2004; Rickabaugh
et al., 2004). Here, we extended this protection to a high-
penetrance cancer. Latency-deficient EBV and KSHV
vaccines therefore deserve serious consideration. The pos-
sibility that gammaherpesviruses contribute to more cancers
than simply those remaining viral genome-positive argues
that such vaccines might greatly benefit human health.
METHODS
Mice. p53
flox/flox (Marino et al., 2000), K-ras
LSL-G12D/+ (Jackson
et al., 2001) and ROSA26-lacZ
flox/flox (Soriano, 1999) mice were
infected with MuHV-4 either i.n. under general anaesthesia
(10
4 p.f.u.) or i.p. (10
6 p.f.u.). All experiments conformed to local
and national ethical regulations. Mice were killed when they showed
macroscopic cancers or other signs of ill health. All mice were
examined post-mortem for clinically inapparent cancers. The PCR
primer sequences for detecting loxP recombination were: p53 – 59-
CACAAAAACAGGTTAAACCCAG and 59-GAAGACAGAAAAGGG-
GAGGG to detect only the recombined locus (612 bp); and k-ras –
59-CCATGGCTTGAGTAAGTCTGC and 59-CGCAGACTGTAGA-
GCAGCG to detect the ‘floxed’ (flanked by loxP sites) G12D k-ras
cassette (550 bp) before but not after recombination, or 59-
GTCTTTCCCCAGCACAGTGC, 59-CTCTTGCCTACGCCACCAGC-
TC and 59-AGCTAGCCACCATGGCTTGAGTAAGTCTGCA to amp-
lify from the floxed G12D k-ras cassette a 500 bp band before
recombination and a 650 bp band after recombination.
Cells. For ex vivo explants, tissues were minced finely and digested
with trypsin before culture. Embryonic fibroblasts were derived
from 14 day embryos. All cells were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum, 2 mM
glutamine, 50 mM b-mercaptoethanol (Sigma), 100 U penicillin
ml
21 and 100 mg streptomycin ml
21. All media and reagents listed
here except b-mercaptoethanol were from PAA Laboratories
GmbH.
Fig. 5. PCR detection of Cre-mediated recombination in samples from Cre
+ MuHV-4-infected p53
flox/floxK-ras
LSL-G12D/+
mice. (a) PCR analysis of the p53 locus of two p53
flox/floxK-ras
LSL-G12D/+ mice, their primary cancers and fibroblast clones
derived from them. The primers amplify the floxed p53 locus only after recombination (612 bp). Identical data were obtained
for a further 10 mice. Negative images of ethidium bromide-stained PCR products are shown. (b) PCR analysis of the floxed
G12D k-ras cassette of the same samples. The primers amplify the cassette (550 bp) before but not after recombination. (c)
Multiplex PCR analysis of the ras locus of the same samples plus additional controls. The primers amplify from the wild-type k-
ras locus a 622 bp band, and from the floxed G12D k-ras cassette a 500 bp band before recombination and a 650 bp band
after recombination. The clones lack the 500 bp band of the parental cancers because they contain no cells with
unrecombined G12D k-ras. WT, p53
flox/floxG12D k-ras
”/” littermate; mut, purified 500 bp band; control DNA, non-transgenic
mice.
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2 MuHV-4 has been described previously (Fowler
et al., 2003). To make Cre
+ MuHV-4, an HCMV IE1 promoter-
driven Cre expression cassette was excised from pGS403 (Smith &
Enquist, 2000) with SalI/SacII, end-repaired and cloned into the
intergenic MfeI site (genomic co-ordinate 77176 of GenBank
accession no. U97553) of a BglII MuHV-4 genomic clone (co-ordinates
75338–78717). All other genomic co-ordinates are also given relative to
GenBank accession no. U97553. The Cre expression cassette plus
genomic flanks was then subcloned with SphI/ScaI (78413–75785) into
the SphI/SmaI sites of pST76K-SR and recombined into an MuHV-4
BAC (Adler et al., 2000). Infectious virus was recovered by transfecting
BAC DNA into BHK-21 cells. The BAC cassette was removed by virus
passage through NIH-3T3-CRE cells (Stevenson et al., 2002) and virus
stocks were grown in BHK-21 cells (de Lima et al., 2004). Replication-
deficient, Cre
+ MuHV-4 was made by digesting a HincII genomic
fragment (63844–70433) in pUC9 with BsmI (67792) and ClaI (69177)
to remove most of ORF50 exon 2 (67661–69376). The Cre coding
sequence plus a 39 poly(A) site from pGS403 was ligated in its place in
frame with the ORF50 AUG. The Cre coding sequence plus genomic
flanks (66120–70433) was then subcloned with KpnI into pST76K-SR,
and recombined into the MuHV-4 BAC. ORF50
2Cre
+ virus was
recovered by transfecting BAC DNA into NIH-3T3-TET50 cells and
inducing ORF50 expression with doxycycline (Milho et al., 2009).
Virus assays. Virus stocks were titrated by plaque assay on BHK-21
cells (de Lima et al., 2004). Latent virus was measured by infectious
centre assay (de Lima et al., 2004). Plaque titres of freeze–thawed
spleen cells were always ,1% of infectious centre assay titres. Viral
genome loads were measured by quantitative PCR (Milho et al.,
2009). Briefly, MuHV-4 genomic co-ordinates 4166–4252 were
amplified from 50–100 ng DNA and quantified by hybridization
with a Taqman probe (genomic coordinates 4218–4189) (Rotor Gene
3000; Corbett Research), in comparison with a standard curve of
cloned plasmid template amplified in parallel. Cellular DNA was
quantified in the same way by amplifying part of the adenosine
phosphoribosyltransferase gene (forward primer, 59-GGGGCAA-
AACCAAAAAAGGA; reverse primer, 59-TGTGTGTGGGGCCTGA-
GTC; probe, 59-TGCCTAAACACAAGCATCCCTACCTCAA).
To quantify viral DNA by Southern blotting, DNA was extracted from
cells (Wizard Genomic DNA purification kit; Promega), digested with
PstI, electrophoresed, transferred to Hybond nylon membranes (Roche
Diagnostics), then probed with a [
32P]dCTP random-primed 1.2 kb PstI
genomic fragment corresponding to the MuHV-4 terminal repeat unit
(Efstathiou et al.,1 9 9 0 ) ,w a s h e d( 6 5uC, 0.2% SSC, 0.1% SDS) and
exposed to X-ray film. Recombinant viruses were analysed qualitatively
for genomic structure in a similar way, except that viral DNA was
digested withBglIIorHindIIIandprobedwithaBglII-restrictedgenomic
fragment (co-ordinates 75338–78717) or the HCMV IE1–Cre construct.
Cells expressing viral tRNAs 1–4 were detected by in situ hybridization
of formaldehyde-fixed, paraffin-embedded spleen cell sections, using a
digoxigenin-labelled riboprobe transcribed from pEH1.4 (Bowden et
al., 1997). Hybridized probe was detected with alkaline phosphatase-
conjugated anti-digoxigenin Fab fragments (Roche Diagnostics).
b-Galactosidase assay. In vitro samples were fixed in 4%
formaldehyde (30 min), then washed in PBS and incubated (3 h,
37 uC) in PBS with 0.01% sodium deoxycholate, 0.02% Nonidet P-
40, 2 mM MgCl2, 4.5 mM potassium ferricyanide, 4.5 mM potassium
ferrocyanide, 1 mg X-Gal ml
21, before washing. In vivo samples were
fixed in 4% formaldehyde (18 h) then frozen in OCT medium,
sectioned, washed in PBS and developed as described above before
washing and mounting.
Immunofluorescence. Cells were plated onto glass cover slides, then
fixed (4% formaldehyde, 30 min), permeabilized (0.1% Triton X-
100, 15 min), blocked (3% BSA in PBS, 15 min) and stained for
syndecan-1, CD44, VCAM-1 (all mAbs from BD Biosciences) or with
the macrophage-specific mAb F4/80 (AbCam) plus Alexa Fluor 568-
conjugated goat anti-rat IgG pAb (Invitrogen), for the MuHV-4
ORF75c using mAb BN-6C12 (Gaspar et al., 2008) plus Alexa Fluor
568-conjugated goat anti-mouse IgG pAb (Invitrogen), for MuHV-4
Fig. 6. Vaccination against MuHV-4-triggered sarcomas. (a)
p53
flox/floxK-ras
LSL-G12D/+ mice were not vaccinated or vaccinated
i.p. with ORF73
”Cre
” MuHV-4, then 2 months later challenged
i.p. with Cre
+ MuHV-4 and followed for cancer incidence.
At 4 months, the vaccinated mice showed no disease. The
data are from one of two equivalent experiments. (b)
p53
flox/floxK-ras
LSL-G12D/+ mice were not vaccinated or vaccinated
i.n. with ORF73
”Cre
” MuHV-4, then 2 months later challenged i.p.
with Cre
+ MuHV-4 as in (a). The data are from one of two
equivalent experiments. (c) In an equivalent experiment to (b),
spleens were were analysed for viral DNA content by quantitative
PCR 1 month after Cre
+ virus challenge. Viral genomes per cell
genome are shown for each mouse (means of three replicate
reactions). The dashed line shows the sensitivity limit of one viral
genome per 500 cell genomes.
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and for Cre recombinase using a polyclonal rabbit serum (AbCam)
plus goat anti-rabbit IgG pAb (Invitrogen). The cells were mounted in
ProLong Gold anti-fade reagent with DAPI (Invitrogen) and imaged
using an Olympus IX70 microscope plus a Retiga 2000R camera line
(QImaging).
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+ MuHV-4. The lungs of vaccinated mice were macroscopically and histologically normal.
Three representative images are shown for each group. Equivalent results were obtained in two further experiments, each with five
mice per group. Bar, 100 mm.
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